Renovo Completes Patient Recruitment In Juvista Phase III Trial
Renovo said that the trial has now recruited over 350 patients from 55 centres in 10 countries: UK, France, Hungary, Germany, Italy, Poland, Spain, Denmark, Latvia and USA.
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).